Results 271 to 280 of about 900,745 (376)

Circulating growth differentiation factor‐15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: A 20‐year follow‐up study

European Journal of Heart Failure, EarlyView.
Summary of the study design and key findings. The (+) and (−) signs mean that the variable has a positive or a negative association with growth differentiation factor‐15 (GDF‐15) levels in the fully adjusted model (age, gender, current smoker, body mass index, total cholesterol, systolic blood pressure and N‐terminal pro‐B‐type natriuretic peptide ...
Luca Monzo, Constance Xhaard, João Pedro Ferreira, Guillaume Baudry, Zohra Lamiral, Kevin Duarte, Erwan Bozec, Jean‐Marc Boivin, Olivier Huttin, Patrick Rossignol, Faiez Zannad, Nicolas Girerd   +11 more
wiley   +1 more source

Uncovering the genetic basis of milk production traits in Mexican Holstein cattle based on individual markers and genomic windows. [PDF]

PLoS One
Cortes-Hernández JG, García-Ruiz A, Peñagaricano F, Montaldo HH, Ruiz-López FJ.   +4 more
europepmc   +1 more source

Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart

European Journal of Heart Failure, EarlyView.
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout   +22 more
wiley   +1 more source

Advances in cytokine gene polymorphisms in tuberculosis. [PDF]

mSphere
Fu H, Sun W, Xu Y, Zhang H.
europepmc   +1 more source

Correction: Single Nucleotide Polymorphism Analysis of European Archaeological DNA.

PLoS ONE, 2010
Claire L. Watson, Elizabeth Popescu, Jesper Boldsen, Mario Slaus, Diana N. J. Lockwood   +4 more
doaj   +1 more source

Single‐nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu‐opioid receptor and may contribute to the genetic risk for addiction

Journal of Neurochemistry, 2010
Ishani Deb, Japashish Chakraborty, P. Gangopadhyay, S. Choudhury, Sumantra Das   +4 more
semanticscholar   +1 more source

Single-nucleotide polymorphism identification and genotyping in [PDF]

core   +1 more source

Electrochemical sensing strategies for on‐site testing of pathogenic nucleic acids

Electrochemical Science Advances, EarlyView.
Abstract Rapid and reliable on‐site pathogen testing is crucial for diagnosing and managing human health. Nucleic acids (NAs) containing genetic information are valuable target molecules for pathogen testing, and sensitive and rapid detection of NAs using electrochemical approaches has been intensively investigated.
Yusuke Kanno, Shuzo Masui, Yusuke Ota, Ryoichi Saito, Takasi Nisisako   +4 more
wiley   +1 more source

Challenging Conventional Diagnostic Methods by Comprehensive Molecular Diagnostics: A Nationwide Prospective Comparison in Children With ALL. [PDF]

JCO Precis Oncol
Boer JM, Koudijs MJ, Kester LA, Sonneveld E, Hehir-Kwa JY, Snijder S, Waanders E, Buijs A, de Haas V, van der Sluis IM, Pieters R, den Boer ML, Tops BBJ.   +12 more
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source